论文部分内容阅读
目的:分析川芎嗪注射液对小儿重症肺炎的疗效及对痰液炎症因子影响。方法:我院儿内科2015年9月~2017年2月期间收治的114例重症肺炎患儿作为对象进行分析,根据入院顺序抽取偶数组为对照组,该组给予常规对症方案治疗,奇数组为观察组,该组在常规治疗基础上加用川芎嗪注射液,分析川芎嗪注射液对患儿疗效的影响。结果:(1)在总有效率上,观察组为96.49%,明显高于对照组80.70%。观察组死亡率5.26%和对照组8.77%比,差异无统计学意义。观察组体温恢复正常、咳嗽消失、呼吸困难消失和肺啰音消失时间分别为(3.19±0.69、6.49±1.27、4.29±1.01、5.86±1.24)d,均明显短于对照组(4.58±1.02、8.30±1.59、6.13±1.15、8.06±1.53)d。(3)治疗后,观察组MMF、PEF、RR分别为(1.69±0.17L/s、2.08±0.21L/s、30.19±3.81次/min),均明显优于对照组(1.24±0.14L/s、1.61±0.16L/s、35.90±4.28次/min)。(4)治疗后,观察组痰液中TNF-ɑ、IL-10水平分别为(22.08±3.51、26.19±5.20)pg/ml,均明显低于对照组(27.69±3.73、32.08±5.42)pg/ml。(5)观察组发生7.02%的不良反应,和对照组8.77%比,差异无统计学意义。结论:川芎嗪注射液可用于小儿重症肺炎的联合用药,其可加快控制患儿炎症,改善肺功能,提高治疗效果。
Objective: To analyze the curative effect of Ligustrazine Injection on pediatric severe pneumonia and its influence on sputum inflammatory factor. Methods: One hundred and seventy-four children with severe pneumonia admitted from September 2015 to February 2017 in our hospital were analyzed. According to the sequence of admission, the even-numbered groups were taken as the control group. The patients in the same group were treated with conventional symptomatic treatment. The odd-numbered groups Observation group, the group on the basis of conventional treatment with ligustrazine injection, analysis of tetramethylpyrazine injection on the efficacy of children. Results: (1) The total effective rate was 96.49% in the observation group and 80.70% in the observation group. The mortality rate of observation group was 5.26% and that of control group was 8.77%, the difference was not statistically significant. The body temperature returned to normal in the observation group, the disappearance of cough, the disappearance of dyspnea and the disappearance of pulmonary rales were (3.19 ± 0.69,6.49 ± 1.27,4.29 ± 1.01,5.86 ± 1.24) days, which were significantly shorter than those in the control group (4.58 ± 1.02, 8.30 ± 1.59, 6.13 ± 1.15, 8.06 ± 1.53) d. (3) After treatment, the MMF, PEF and RR in the observation group were significantly higher than those in the control group (1.24 ± 0.14L / s, 2.08 ± 0.21L / s, 30.19 ± 3.81 / min) s, 1.61 ± 0.16 L / s, 35.90 ± 4.28 times / min). (4) After treatment, the levels of TNF-ɑ and IL-10 in sputum of observation group were (22.08 ± 3.51,26.19 ± 5.20) pg / ml, which were significantly lower than those of control group (27.69 ± 3.73,32.08 ± 5.42) pg / ml. (5) The observation group had a 7.02% adverse reaction, compared with 8.77% in the control group, the difference was not statistically significant. Conclusion: Ligustrazine injection can be used in children with severe pneumonia combined medication, which can speed up the control of children with inflammation, improve lung function and improve the therapeutic effect.